Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CBO Legislative Scores Will Account For Medicare Rx’s Reductions In Other Medical Costs

This article was originally published in The Pink Sheet Daily

Executive Summary

In a policy change, the Congressional Budget Office, which estimates the impact of legislation on federal spending, will account for pharmaceuticals’ effect on overall medical spending in Medicare for bills that directly affect drug use.

You may also be interested in...



Reimbursement Briefs: Medicaid Savings, Kcentra Payment, Formulary Discrimination Concerns

Cost reductions in Medicaid associated with increased drug use; Medicare add-on payments for Kcentra extended; patient groups seek formulary non-discrimination provisions in HHS rule.

The Sovaldi Anniversary? Burgess Wants Part D Milestone To Change How Gov’t Values Rx Spending

Congressional budget projections should use longer time horizons, Vice-Chair of House Energy and Commerce Health Subcommittee argues; meanwhile former FDA Commissioner suggests costly drugs could be paid for on a mortgage model.

Medication Therapy Management To Expand In Part D Under CMS Rule

CMS expects the proposed changes to medication therapy management will make 55% of Medicare beneficiaries eligible for MTM services, which CMS says has been shown to improve drug therapy outcomes and reduce health care costs.

Related Content

Topics

UsernamePublicRestriction

Register

PS073566

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel